Overview of Granisetron Injection:

VOMIPRA-G Injection contains Granisetron 3mg.
Granisetron has proved safe and effective in controlling chemotherapy-induced emesis and is more convenient to administer than conventional antiemetics.

Granisetron is a serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients.

VOMIPRA-G Injection can be used in the prevention and treatment of the following conditions:

  • Acute nausea and vomiting associated with chemotherapy and radiotherapy.
  • Post-operative nausea and vomiting.

A dose of 1-3 mg (10-40 μg/kg) of VOMIPRA-G Injection should be administered either as a slow intravenous injection or as a diluted intravenous infusion and administered over 5 minutes, or 5 minutes prior to the start of chemotherapy. The solution should be diluted to 5ml per mg.

Further maintenance doses may be administered at least 10 minutes apart. The maximum dose to be administered over 24 hours should not exceed 9 mg.

Granisetron is a potent, selective antagonist of 5-HT3 receptors. The antiemetic activity of the drug is brought about through the inhibition of 5-HT3 receptors present both centrally (medullary chemoreceptor zone) and peripherally (GI tract). This inhibition of 5-HT3 receptors in turn inhibits the visceral afferent stimulation of the vomiting center, likely indirectly at the level of the area postrema, as well as through direct inhibition of serotonin activity within the area postrema and the chemoreceptor trigger zone.